Roberto Butera
Overview
Explore the profile of Roberto Butera including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
155
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van der Straat R, Draijer R, Surmiak E, Butera R, Land L, Magiera-Mularz K, et al.
RSC Med Chem
. 2024 Apr;
15(4):1210-1215.
PMID: 38665826
The progress in cancer survival and treatment has witnessed a remarkable transformation through the innovative approach of targeting the inhibitory immune checkpoint protein PD-1/PD-L1 complex by mAbs, pembrolizumab (Keytruda). While...
2.
Wazynska M, Butera R, Requesens M, Plat A, Zarganes-Tzitzikas T, Neochoritis C, et al.
J Med Chem
. 2023 Jul;
66(14):9577-9591.
PMID: 37450644
In search of a potent small molecular PD-L1 inhibitor, we designed and synthesized a compound based on a 2-hydroxy-4-phenylthiophene-3-carbonitrile moiety. Ligand's performance was tested in vitro and compared side-by-side with...
3.
Shaabani S, Gadina L, Surmiak E, Wang Z, Zhang B, Butera R, et al.
Molecules
. 2022 Jun;
27(11).
PMID: 35684392
New biphenyl-based chimeric compounds containing pomalidomide were developed and evaluated for their activity to inhibit and degrade the programmed cell death-1/programmed cell death- ligand 1 (PD-1/PD-L1) complex. Most of the...
4.
Butera R, Wazynska M, Magiera-Mularz K, Plewka J, Musielak B, Surmiak E, et al.
ACS Med Chem Lett
. 2021 May;
12(5):768-773.
PMID: 34055224
The PD-1/PD-L1 axis has proven to be a highly efficacious target for cancer immune checkpoint therapy with several approved antibodies. Also, small molecules based on a biphenyl core can antagonize...
5.
Butera R, Shrinidhi A, Kurpiewska K, Kalinowska-Tluscik J, Domling A
Chem Commun (Camb)
. 2020 Aug;
56(73):10662-10665.
PMID: 32785316
Oligoisocyanides are attractive synthetic targets, however, only a few are known. Here, we describe the smallest stable tetraisocyanide possible, the 1,3-diisocyano-2,2-bis(isocyano-methyl)propane (1) with S4 symmetry. Its four-step synthesis, structure, and...
6.
Wang Q, Osipyan A, Konstantinidou M, Butera R, Mgimpatsang K, Shishkina S, et al.
J Org Chem
. 2020 Jun;
85(12):8295.
PMID: 32519856
No abstract available.
7.
Wang Q, Osipyan A, Konstantinidou M, Butera R, Mgimpatsang K, Shishkina S, et al.
J Org Chem
. 2019 Aug;
84(18):12148-12156.
PMID: 31433186
Here we describe a facile, tandem synthetic route for indolo[3,2-]quinolinones, a class of natural alkaloid analogues of high biological significance. A Ugi four-component reaction with indole-2-carboxylic acid and an aniline...
8.
Guzik K, Tomala M, Muszak D, Konieczny M, Hec A, Blaszkiewicz U, et al.
Molecules
. 2019 Jun;
24(11).
PMID: 31151293
Cancer immunotherapy based on antibodies targeting the immune checkpoint PD-1/PD-L1 pathway has seen unprecedented clinical responses and constitutes the new paradigm in cancer therapy. The antibody-based immunotherapies have several limitations...
9.
Shaabani S, Huizinga H, Butera R, Kouchi A, Guzik K, Magiera-Mularz K, et al.
Expert Opin Ther Pat
. 2018 Aug;
28(9):665-678.
PMID: 30107136
Introduction: The protein-protein interaction PD1/PD-L1 is an important immune checkpoint and several recently approved monoclonal antibodies show promising anti cancer activities in the clinical practice. However, only a small percentage...